Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

GIP and glucagon. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. Tirzepatide, the active ingredient in Eli Lilly's weight loss ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly makes some of the most powerful weight ... Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that our bodies produce naturally, albeit in very small ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.